Get the Stockscreener App
2.05
4.65%
-0.10
After Hours:
2.09
0.04
+1.95%
Overview
News
Price History
Option Chain
Financials
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is traded at $2.05, with a volume of 557.94K.
It is down -4.65% in the last 24 hours and down -3.30% over the past month.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
See More
Previous Close:
$2.15
Open:
$2.15
24h Volume:
557.94K
Relative Volume:
0.60
Market Cap:
$99.03M
Revenue:
-
Net Income/Loss:
$-97.22M
P/E Ratio:
-1.4855
EPS:
-1.38
Net Cash Flow:
$-82.44M
1W Performance:
+8.47%
1M Performance:
-3.30%
6M Performance:
-11.64%
1Y Performance:
-12.02%
1-Day Range:
$2.04
$2.17
1-Week Range:
$1.915
$2.22
52-Week Range:
$1.15
$4.98
Cassava Sciences Inc Stock (SAVA) Company Profile
Name
Cassava Sciences Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
2.05 | 103.86M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Cassava Sciences Inc Stock (SAVA) Latest News
Fed Watch: What are Cassava Sciences Incs technical support levelsJuly 2025 Retail & High Win Rate Trade Tips - baoquankhu1.vn
Cassava Sciences And 2 Other Promising Penny Stocks - Yahoo Finance
Cassava Sciences Target of Unusually High Options Trading (NASDAQ:SAVA) - MarketBeat
Cassava Sciences (NASDAQ:SAVA) Upgraded to Hold at Wall Street Zen - MarketBeat
Setup Watch: Is Cassava Sciences Inc Equity Warrant subject to activist investor interestJuly 2025 Gainers & Smart Swing Trading Alerts - baoquankhu1.vn
Is Cassava Sciences Inc. stock influenced by commodity prices2025 Bull vs Bear & High Accuracy Investment Signals - mfd.ru
What are Cassava Sciences Inc.’s technical support levelsJuly 2025 Analyst Calls & Expert Verified Stock Movement Alerts - mfd.ru
Stock Analysis: Does Cassava Sciences Inc Equity Warrant have pricing powerRecession Risk & Smart Money Movement Alerts - baoquankhu1.vn
Setup Watch: What is Cassava Sciences Inc Equity Warrants book value per shareGold Moves & High Accuracy Swing Trade Signals - baoquankhu1.vn
Cassava Sciences (NASDAQ:SAVA) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Retail Surge: What are the future prospects of Cassava Sciences Inc Equity Warrant2025 Retail Activity & Free Community Consensus Stock Picks - baoquankhu1.vn
The Truth About Cassava Sciences: Wall Street’s Wildcard Stock Everyone Keeps Arguing About - AD HOC NEWS
Aug Retail: What is Cassava Sciences Inc Equity Warrants book value per shareDollar Strength & Verified Trade Idea Suggestions - baoquankhu1.vn
Energy Moves: Is Cassava Sciences Inc backed by strong institutional buyingDay Trade & Daily Stock Trend Reports - baoquankhu1.vn
Cassava Sciences publishes phase 3 Alzheimer’s trial results in JPAD By Investing.com - Investing.com Nigeria
RSI Check: How Cassava Sciences Inc stock trades during market volatilityEarnings Performance Report & Smart Swing Trading Alerts - Bộ Nội Vụ
Cassava Sciences publishes phase 3 Alzheimer’s trial results in JPAD - Investing.com
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease - Yahoo Finance
Cassava Announces Publication of Peer-Reviewed Phase 3 - GlobeNewswire
Will Cassava Sciences Inc. stock benefit from sector rotationMarket Trend Summary & Smart Money Movement Alerts - ulpravda.ru
What valuation multiples suggest for Cassava Sciences Inc. Equity Warrant stockJuly 2025 Summary & AI Based Buy and Sell Signals - ulpravda.ru
Why Cassava Sciences Inc. Equity Warrant stock remains a top recommendationJuly 2025 Weekly Recap & High Return Trade Guides - ulpravda.ru
How Cassava Sciences Inc. (PX91) stock reacts to weak economyMarket Volume Report & Verified Momentum Watchlists - Улправда
Why Cassava Sciences Inc. (PX91) stock is a must watch tickerWeekly Trend Summary & Trade Opportunity Analysis Reports - Улправда
Signal Recap: Why Cassava Sciences Inc. Equity Warrant stock appeals to analystsJuly 2025 Trends & Growth Focused Stock Pick Reports - Улправда
Trend Review: What valuation ratios show for Cassava Sciences Inc. (PX91) stockWeekly Profit Report & Safe Entry Momentum Stock Tips - Улправда
Is Cassava Sciences Inc. stock a dividend growth opportunity - ulpravda.ru
How Cassava Sciences Inc. stock responds to policy changesJuly 2025 Trends & Reliable Price Breakout Alerts - Улправда
Published on: 2026-01-09 03:02:15 - Улправда
Does Cassava Sciences Inc. Equity Warrant stock trade at a discount to peers2025 Market Sentiment & Free Verified High Yield Trade Plans - Улправда
Why Cassava Sciences Inc. Equity Warrant stock appeals to analystsMarket Trend Report & Technical Pattern Based Signals - Улправда
Why Cassava Sciences Inc. Equity Warrant stock is in analyst buy zoneJuly 2025 Reactions & Entry Point Confirmation Signals - Улправда
Investors Buy Large Volume of Call Options on Cassava Sciences (NASDAQ:SAVA) - MarketBeat
2026 world cup star players odds: Why Cassava Sciences Inc. Equity Warrant stock remains undervalued2026 world cup usa national team round of 16 playmakers counter attacking expert forecast expert opinion - Улправда
Sector Leaders Rotate Capital Into VCU Data Management LimitedTop Performing Stocks & Free Significant Capital Appreciation - Early Times
Aug Reactions: Will Cassava Sciences Inc stock reach all time highs in 2025Market Sentiment Review & Low Volatility Stock Suggestions - moha.gov.vn
Multi Factor Analysis Ranks Ekansh Concepts Limited as Strong BuyStock Price Targets & Register for the Next Free Workshop - earlytimes.in
Quarterly Earnings: Will Cassava Sciences Inc stock see insider buyingInsider Selling & Weekly Watchlist for Hot Stocks - moha.gov.vn
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - The Malaysian Reserve
Cassava Sciences settles securities class action for $31.25 million By Investing.com - Investing.com Australia
Cassava Sciences agrees to settle long-running investor lawsuit - The Business Journals
Cassava Sciences agrees to $31.25 million settlement in securities class action By Investing.com - Investing.com Nigeria
Cassava Sciences agrees to $31.25 million settlement in securities class action - Investing.com
Cassava Sciences Agrees to Pay $31.25 Million to Settle Securities Class Action - marketscreener.com
[8-K] CASSAVA SCIENCES INC Reports Material Event | SAVA SEC FilingForm 8-K - Stock Titan
Cassava settles securities class action suit (SAVA:NASDAQ) - Seeking Alpha
Cassava Sciences settles securities class action for $31.25 million - Investing.com
Cassava Sciences, Inc. Reaches $31.25 Million Settlement in Consolidated Securities Class Action Litigation - Quiver Quantitative
Cassava announces agreement to settle securities class action litigation - marketscreener.com
Cassava Announces Agreement to Settle Securities Class Action Litigation - GlobeNewswire
Cassava Sciences Shares Plunge After FDA Intervention - AD HOC NEWS
Cassava Sciences Inc Stock (SAVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):